Alpha 2.0
Login Register
» Authors » H Mitsuya

H Mitsuya

Explore the profile of H Mitsuya including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 352
Citations 4845
Followers 0
Related Specialties
Urology
General Medicine
Pharmacology
Top 10 Co-Authors
S Broder
K Miyake
R Yarchoan
T Murase
D G Johns
T Shirasaka
A Kondo
M Takashi
M Yamamoto
J S Driscoll
Published In
Hinyokika Kiyo
Nihon Hinyokika Gakkai Zasshi
J Med Chem
Proc Natl Acad Sci U S A
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
11.
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation
Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N
Leukemia . 2005 Jul; 19(9):1673-5. PMID: 16049512
No abstract available.
12.
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, et al.
Leukemia . 2005 May; 19(8):1361-6. PMID: 15902284
AML1-MTG8 generated by t(8;21) contributes to leukemic transformation, but additional events are required for full leukemogenesis. We examined whether mutations in the receptor tyrosine kinase (RTK) pathway could be the...
13.
A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia
Matsuno N, Nanri T, Kawakita T, Mitsuya H, Asou N
Leukemia . 2004 Dec; 19(3):480-1. PMID: 15625552
No abstract available.
14.
Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics
Matsuno N, Hoshino K, Nanri T, Kawakita T, Mitsuya H, Asou N
Leukemia . 2004 Apr; 18(6):1146-8. PMID: 15085158
No abstract available.
15.
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype
Matsuno N, Osato M, Yamashita N, Yanagida M, Nanri T, Fukushima T, et al.
Leukemia . 2003 Oct; 17(12):2492-9. PMID: 14562119
Point mutations of the transcription factor AML1 are associated with leukemogenesis in acute myeloblastic leukemia (AML). Internal tandem duplications (ITDs) in the juxtamembrane domain and mutations in the second tyrosine...
16.
Synthesis of 4'-ethynyl-purine nucleosides possessing anti-HIV activity
Kitano K, Sakata S, Kohgo S, Matsuoka M, Kodama E, Mitsuya H, et al.
Nucleic Acids Symp Ser . 2003 Aug; (44):105-6. PMID: 12903290
Searching for more effective anti-HIV agents, we have prepared 4'-ethynyl-purine nucleosides. They were derived in several steps from 4-C-triethylsilylethynyl ribose, which was used as an intermediate in the synthesis of...
17.
4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants
Ohrui H, Mitsuya H
Curr Drug Targets Infect Disord . 2002 Nov; 1(1):1-10. PMID: 12455229
In the past years, a variety of 4'-C-substituted-2'-deoxynucleosides (4'SdNs) were designed, synthesized, and examined as potential therapeutics against human immunodeficiency virus (HIV) infection and certain such analogues proved to exert...
18.
[Severe combined immunodeficiency disease and similar combined immunodeficiency disease]
Nakata H, Mitsuya H
Nihon Rinsho . 2002 Jan; 59 Suppl 7:581-7. PMID: 11808170
No abstract available.
19.
Synthesis of the L-enantiomer of 4'-C-ethynyl-2'-deoxycytidine
Kohgo S, Mitsuya H, Ohrui H
Biosci Biotechnol Biochem . 2001 Oct; 65(8):1879-82. PMID: 11577734
The L-enantiomer of 4'-C-ethynyl-2'-deoxycytidine (2) was synthesized, but did not show any activity against HIV-1 up to 100 microM.
20.
Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor SDF-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells
Suzuki Y, Rahman M, Mitsuya H
J Immunol . 2001 Sep; 167(6):3064-73. PMID: 11544290
Stromal cell-derived factor (SDF)-1 is a ligand for the chemokine receptor CXCR4 which is broadly expressed in lymphocytes, but the effects of SDF-1 on T cells are largely unknown. When...